Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5152650 | 0.83 | ABL1 (0.43) | TP53 | |
| SCHEMBL5149232 | 0.82 | RET (0.35) | FGFR1FGFR2FGFR3TP53 | |
| SCHEMBL5147962 | 0.80 | USP8 (0.46) | FGFR1FGFR2FGFR3TP53 | |
| SCHEMBL5147922 | 0.80 | USP8 (0.46) | FGFR1FGFR2FGFR3TP53 | |
| SCHEMBL5149167 | 0.80 | ADORA2A (0.35) | FGFR1FGFR2FGFR3TP53 | |
| SCHEMBL5149150 | 0.79 | GRM5 (0.36) | — | |
| SCHEMBL5147958 | 0.78 | ADORA2A (0.39) | FGFR1FGFR2FGFR3PDE4APDE4D | |
| SCHEMBL5150959 | 0.77 | FGFR1 (0.39) | FGFR1FGFR2FGFR3TP53 | |
| SCHEMBL5147937 | 0.76 | TP53 (0.37) | TP53 | |
| SCHEMBL5147966 | 0.76 | ADORA2B (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265120-B2 | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | ADORA2A, HTR5A, ADORA1 | FGFR1 2680/4885FGFR2 3554/4885FGFR3 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.